Privi Speciality Chemicals Limited — PPTs, 12-02-2025: Investor Presentation

**Financial Highlights:** Privi Speciality Chemicals Limited reported a 16% year-on-year increase in revenue to ₹1,493 Cr for the nine months ending December 31, 2024, and a 20% increase to ₹493 Cr for Q3 FY25. EBITDA rose 29% to ₹327 Cr for the nine-month period and 20% to ₹115 Cr for Q3 FY25. Profit After Tax (PAT) surged 90% to ₹121 Cr for nine months and 55% to ₹44 Cr for Q3, achieving margins of 21.88% and 9.02%, respectively.

**Strategic Initiatives and Growth Drivers:** The company is focused on enhancing production capabilities and operational efficiencies, driving an impressive 33% volume growth across product segments. Its recent receipt of the Trishul Award reflects its strong export performance, while a higher CDP score indicates increasing commitment to sustainability and transparency.

**Business Developments:** A new joint venture with Givaudan SA has been established, highlighting a strategic partnership to produce 40 exclusive fragrance products, with project Capex at ₹178 Cr aimed at capturing higher market value.

**Market Position and Competitive Advantage:** Privi maintains a leading position in the global aroma chemicals market, particularly in products like DHMOL and Amber Fleur, benefiting from a diversified client base and robust backward integration.

**Investor Implications:** The positive financial trajectory and strategic initiatives position the company favorably for potential growth, suggesting that investors should remain watchful of further developments in production and market expansion.